These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36330085)

  • 1. Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis.
    Cherian JJ; Eerike M; Bagepally BS; Das S; Panda S
    Front Pharmacol; 2022; 13():1004308. PubMed ID: 36330085
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of tocilizumab and baricitinib among patients hospitalized for COVID-19: a systematic review and meta-analysis.
    Zhang J; Fan X; Zhang X; Jiang F; Wu Y; Yang B; Li X; Liu D
    Front Pharmacol; 2023; 14():1293331. PubMed ID: 38074144
    [No Abstract]   [Full Text] [Related]  

  • 3. Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.
    Bryushkova EA; Skatova VD; Mutovina ZY; Zagrebneva AI; Fomina DS; Kruglova TS; Akopyan AA; Strazhesko ID; Lukyanov SA; Tkacheva ON; Lysenko MA; Chudakov DM
    PLoS One; 2022; 17(8):e0273340. PubMed ID: 36001576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19.
    Masiá M; Padilla S; García JA; García-Abellán J; Navarro A; Guillén L; Telenti G; Mascarell P; Botella Á; Gutiérrez F
    Front Med (Lausanne); 2021; 8():749657. PubMed ID: 34820393
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis.
    Albuquerque AM; Eckert I; Tramujas L; Butler-Laporte G; McDonald EG; Brophy JM; Lee TC
    Clin Microbiol Infect; 2023 Jan; 29(1):13-21. PubMed ID: 35863630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Choosing immunomodulating therapies for the treatment of COVID-19: recommendations based on placebo-controlled trial evidence.
    Sweeney DA; Lobo SM; Póvoa P; Kalil AC
    Clin Microbiol Infect; 2024 May; 30(5):611-618. PubMed ID: 38182048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial.
    Karampitsakos T; Papaioannou O; Tsiri P; Katsaras M; Katsimpris A; Kalogeropoulos AP; Malakounidou E; Zarkadi E; Tsirikos G; Georgiopoulou V; Sotiropoulou V; Koulousousa E; Chourpiliadi C; Matsioulas A; Lagadinou M; Sampsonas F; Akinosoglou K; Marangos M; Tzouvelekis A
    Clin Microbiol Infect; 2023 Mar; 29(3):372-378. PubMed ID: 36273769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone.
    Wong CKH; Lau KTK; Au ICH; Xiong X; Chung MSH; Leung BYC; Lau EHY; Cowling BJ
    Front Pharmacol; 2022; 13():866441. PubMed ID: 35707401
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes among Hospitalized COVID-19 Patients Who Received Baricitinib or Tocilizumab in Addition to Standard of Care.
    Walker CP; Hurlock NP; Deb S
    Diseases; 2024 May; 12(5):. PubMed ID: 38785762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Efficacy and Safety of Janus Kinase Inhibitors for Patients With COVID-19: A Living Systematic Review and Meta-Analysis.
    Zhang X; Shang L; Fan G; Gu X; Xu J; Wang Y; Huang L; Cao B
    Front Med (Lausanne); 2021; 8():800492. PubMed ID: 35155477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Immunomodulators in Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Ngamprasertchai T; Kajeekul R; Sivakorn C; Ruenroegnboon N; Luvira V; Siripoon T; Luangasanatip N
    Infect Dis Ther; 2022 Feb; 11(1):231-248. PubMed ID: 34757578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort.
    Karolyi M; Gruebl A; Omid S; Saak M; Pawelka E; Hoepler W; Kelani H; Kuran A; Laferl H; Ott C; Pereyra D; Santol J; Seitz T; Traugott M; Assinger A; Wenisch C; Zoufaly A
    Infection; 2023 Aug; 51(4):851-858. PubMed ID: 36083403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baricitinib versus tocilizumab in critically ill COVID-19 patients: A retrospective cohort study.
    Conroy GM; Bauer SR; Pallotta AM; Duggal A; Wang L; Sacha GL
    Pharmacotherapy; 2024 Jan; 44(1):28-38. PubMed ID: 37593883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19.
    Reid NK; Joyner KR; Lewis-Wolfson TD
    Ann Pharmacother; 2023 Jul; 57(7):769-775. PubMed ID: 36314277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Tocilizumab vs Baricitinib in Clinical Outcomes Among Hospitalized Patients With COVID-19: Experience From a Public Hospital System in New York City.
    Sunny S; Tran A; Lee J; Abdallah M; Chaudhry N; Quale J
    Open Forum Infect Dis; 2023 Aug; 10(8):ofad426. PubMed ID: 37608917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study.
    Kojima Y; Nakakubo S; Takei N; Kamada K; Yamashita Y; Nakamura J; Matsumoto M; Horii H; Sato K; Shima H; Suzuki M; Konno S
    Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454352
    [No Abstract]   [Full Text] [Related]  

  • 18. Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study.
    Roddy J; Wells D; Schenck K; Santosh S; Santosh S
    Crit Care Explor; 2022 May; 4(5):e0702. PubMed ID: 35783551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis.
    Sun J; Wang S; Ma X; Wei Q; Peng Y; Bai Y; Miao G; Meng C; Liu P
    Eur J Med Res; 2023 Nov; 28(1):536. PubMed ID: 37990249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis.
    Yu SY; Koh DH; Choi M; Ryoo S; Huh K; Yeom JS; Yoon YK
    Emerg Microbes Infect; 2022 Dec; 11(1):1154-1165. PubMed ID: 35343397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.